Lepu Medical 2026H1: Revenue of RMB 3.214 billion, down 4.61% YoY, Net Profit Attributable to Shareholders of the Parent Company down 27.71% YoY.

Source: Lepu Medical 2026 Semi-Annual Report

Operating revenue 3.214 billion yuan (-4.61%) / Net Profit Attributable to Shareholders of the Parent Company 499 million yuan (-27.71%) / Financial expenses surged 177.00% year-on-year to 172 million yuan

DentalGoodNews｜August 22, 2026, Lepu Medical (300003.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved operating revenue of 3.214 billion yuan, a year-on-year decrease of 4.61%; net profit attributable to shareholders of the listed company (Net Profit Attributable to Shareholders of the Parent Company) was 499 million yuan, a year-on-year decrease of 27.71%.

In terms of financial data, the company's net profit attributable to shareholders of the parent company after deducting Non-recurring Gains and Losses was 481 million yuan, a year-on-year decrease of 27.40%; Net Cash Flow from Operating Activities was 633 million yuan, a year-on-year decrease of 0.60%. Affected by one-time expenses from convertible bond redemption, the company's financial expenses increased by 177.00% year-on-year to 172 million yuan. According to previous reports by DGN, Lepu Medical's full-year 2026 Net Profit Attributable to Shareholders of the Parent Company increased by approximately 290% year-on-year. Entering the first half of 2026, affected by one-time expenses from convertible bond redemption and the decline in pharmaceutical preparation business, the company's Net Profit Attributable to Shareholders of the Parent Company turned to a year-on-year decrease.

In terms of asset structure, as of the end of the reporting period, the company's total assets were 26.173 billion yuan, an increase of 0.13% from the beginning of the period; net assets attributable to shareholders of the listed company were 16.398 billion yuan, an increase of 1.75% from the beginning of the period; Weighted Average Return on Equity (ROE) was 3.05%, a decrease of 1.38 percentage points compared with the same period last year.

Source: Lepu Medical 2026 Semi-Annual Report

In terms of business structure, during the reporting period, the Medical Devices segment achieved operating revenue of 1.715 billion yuan, a year-on-year decrease of 3.47%. The pharmaceutical segment achieved operating revenue of 961 million yuan, a year-on-year decrease of 14.01%, of which preparation (generic drug) business revenue was 806 million yuan, a year-on-year decrease of 17.32%; API business revenue was 155 million yuan, a year-on-year increase of 8.74%. The medical services and health management segment achieved operating revenue of 538 million yuan, a year-on-year increase of 13.24%. In terms of international business, the company's overseas operating revenue was 598 million yuan, a year-on-year increase of 14.45%, accounting for approximately 18.62% of total operating revenue.

As of the end of the reporting period, the company's Medical Devices segment had accumulated 2,411 patent applications, with over 600 products listed domestically and internationally, 709 Class II and III Medical Device Registration Certificates approved by NMPA, 35 US FDA approvals, and 196 EU CE certifications.